EUVIMEDEUVIMED entdecken
Crossref

Perilymphatic Signal Changes in Vestibular Schwannoma: A Potential Biomarker of Progressive Hearing Loss?

Anne Renée Juliette Péporté, Benoît Gallix, Aïna Venkatasamy

Otolaryngology–Head and Neck Surgery · 2025

DOI: 10.1002/ohn.1228 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2025. Verfasst von Anne Renée Juliette Péporté und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Cantonal Hospital Frauenfeld, Frauenfeld, Switzerland. Hauptthemen laut MEDLINE: Neuroma, Acoustic, Magnetic Resonance Imaging, Perilymph, Hearing Loss. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Vestibular schwannomas influence the magnetic resonance (MR) signal intensity (SI) in the vestibular cistern and cochlear perilymph. The aim of this study is to evaluate the relationship between perilymphatic signal changes on gradient‐echo T2‐weighted 3 T MR sequence and the clinical symptoms. Study Design Retrospective case‐control study.

Setting

The study was conducted at the Institute of Image‐Guided Surgery in Strasbourg, France.

Methods

Patients with vestibular schwannoma who underwent magnetic resonance imaging at our institution between 2008 and 2016 were retrospectively reviewed. A control group consisted of individuals without past or present otological symptoms. The vestibular schwannomas were divided into three groups, based on the degree of internal auditory canal obstruction. The SI ratios of the vestibular cistern to cerebrospinal fluid (CSF) and cochlea to CSF were compared with clinical data.

Results

We included 172 patients with vestibular schwannoma and 61 controls. Vestibular schwannoma was associated with a significant decrease of the SI ratio of the vestibular cistern to CSF (0.716 ± 0.297 vs 1.06 ± 0.21, P = .004) and cochlea to CSF (0.66 ± 0.199 vs 0.903 ± 0.011, P = .004) compared to controls, with significant negative correlation between both the SI ratios of the vestibular cistern and cochlea to CSF with tumor volume ( P < .001). Among all the symptoms studied, the SI ratio of the cistern normalized by CSF was significantly associated with progressive hearing loss ( P = .003).

Conclusion

Perilymphatic vestibular cistern and cochlear SI changes appear to be a promising noninvasive biomarker for hearing impairment in vestibular schwannoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroma, AcousticMagnetic Resonance ImagingPerilymphHearing LossHumansFemaleMaleRetrospective StudiesMiddle AgedCase-Control StudiesAdultAgedDisease ProgressionBiomarkers

Stichwörter der Autor:innen

biomarkerhearing lossmagnetic resonance imagingperilymphvestibular schwannoma

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Radiology, Cantonal Hospital Frauenfeld, Frauenfeld, Switzerland.
  • Department of Radiology, Faculté de médecine, Université de Strasbourg, Strasbourg, France.
  • American Hospital of Paris, Neuilly-sur-Seine, France.
  • INRIA, Institut national de recherche en sciences et technologies du numérique, Paris, France.
  • Department of Diagnostic Radiology, Montreal General Hospital Site, Mc Gill University, Montreal, Québec, Canada.
  • Department of Radiology, Institute of Image-Guided Surgery, Strasbourg, France.

Zitieren

APA

Péporté, A. R. J., Gallix, B., & Venkatasamy, A. (2025). Perilymphatic Signal Changes in Vestibular Schwannoma: A Potential Biomarker of Progressive Hearing Loss?. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.1228

Vancouver

Péporté ARJ, Gallix B, Venkatasamy A. Perilymphatic Signal Changes in Vestibular Schwannoma: A Potential Biomarker of Progressive Hearing Loss?. Otolaryngology–Head and Neck Surgery. 2025. doi:10.1002/ohn.1228

BibTeX
@article{Pport2025,
  author = {Péporté, Anne Renée Juliette and Gallix, Benoît and Venkatasamy, Aïna},
  title = {Perilymphatic Signal Changes in Vestibular Schwannoma: A Potential Biomarker of Progressive Hearing Loss?},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2025},
  doi = {10.1002/ohn.1228}
}
Kostenlos starten →